home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

25.81 -0.22 (-0.85%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Immunovant, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024 ↗

May 29, 2024

IMVT stock results show that Immunovant missed analyst estimates for earnings per share the fourth quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 29, 2024

Via Benzinga

Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study ↗

May 29, 2024

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

Via Benzinga

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 29, 2024

Via Benzinga

Recap: Immunovant Q3 Earnings ↗

February 12, 2024

Via Benzinga

Argenx Dives On Autoimmune Therapy Failure ↗

December 20, 2023

A treatment for a skin-blistering condition failed to beat a placebo.

Via Investor's Business Daily

Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday ↗

May 29, 2024

Via Benzinga

Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump ↗

May 29, 2024

The company says it's still running additional testing of the drug, calling the results "positive."

Via Investor's Business Daily

Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗

March 25, 2024

Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.

Via InvestorPlace

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results ↗

March 21, 2024

Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.

Via Investor's Business Daily

Analyst Ratings for Immunovant ↗

December 01, 2023

Via Benzinga

Where Immunovant Stands With Analysts ↗

November 15, 2023

Via Benzinga

Recap: Immunovant Q2 Earnings ↗

November 09, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 21, 2024

Via Benzinga

3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 ↗

February 26, 2024

Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.

Via InvestorPlace

7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 ↗

February 06, 2024

Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge.

Via InvestorPlace

3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024 ↗

January 19, 2024

Analyst ratings tell investors which stocks institutional investors like, here are three top-rated Russell 2000 stocks to consider in 2024

Via InvestorPlace

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗

January 15, 2024

These five biotech companies could have a lot of room to run.

Via The Motley Fool

Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review ↗

December 22, 2023

Despite a Wednesday tumble, the major indexes are right at 2023 highs.

Via Investor's Business Daily

Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

December 21, 2023

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.

Via Benzinga

Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off ↗

December 21, 2023

Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday.

Via Investor's Business Daily

Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% ↗

December 21, 2023

Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in

Via Benzinga

Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 21, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session ↗

December 21, 2023

U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday.

Via Benzinga

Topics Stocks

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

December 20, 2023

From Roivant Sciences

Via GlobeNewswire

Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 20, 2023

Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.

Via Benzinga

FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

December 20, 2023

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.

Via Benzinga

Topics Stocks

Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review ↗

December 01, 2023

Software earnings were strong, while the Fed is shifting toward rate cuts.

Via Investor's Business Daily

Topics Economy Stocks

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

November 28, 2023

From Roivant Sciences

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023 ↗

October 13, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com